Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 08:30 ET | Source: HepaRegeniX

HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia...
April 15, 2025 05:00 ET | Source: HepaRegeniX

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing...
July 10, 2024 03:00 ET | Source: HepaRegeniX GmbH

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...
March 14, 2024 11:35 ET | Source: HepaRegeniX GmbH

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniXHRX-215 proved to be safe and...